All News

RheumNow Podcast square

Don’t Buy Guitars (12.6.2024)

Jack Cush, MD

This year at ACR24, the RheumNow faculty and reporters were prolific, generating >800 Tweets, 56 written articles, 117 Videos and 28 podcasts – all in 4 days! You can best review and learn ACR24 by A) Rheumatology Roundup; b) Topic Panel videos; and c) Topic podcasts.

Read Article
DLE discoid lupus

Challenge in Measuring Cutaneous Lupus Activity and Severity

Jack Cush, MD

JAMA Dermatology features a discussion by Drs. McMichael and Frey on measuring lupus skin disease in clinical trials and practice using the validated Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI).

Read Article
Roundup cover

ACR24: Rheumatology Roundup

Jack Cush, MD

Join Drs. Jack Cush and Artie Kavanaugh as they review 15+ presentations and abstracts from the 2024 ACR Convergence meeting in Washington, DC.

Read Article
Stills,continuum

​​Standardizing Still’s Disease Research: Global Data Harmonization Needed

Bella Mehta, MBBS, MS

A recent study presented at #ACR24 convergence highlights significant gaps and inconsistencies in the research of systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease (AOSD).

Read Article
temperature.fever_.weather.jpg

A Polygenic Model for Still's Disease

Jack Cush, MD

Adult-onset Still's disease (AOSD) is systemic autoinflammatory disorder of unknown etiology.  It is considered among the febrile autoinflammatory etiologies.

Read Article
Kawasaki.jpg

Diagnosis and Management of Kawasaki Disease

EurekAlert!

The journal Circulation has published a comprehensive overview called “Update on Diagnosis and Management of Kawasaki Disease,” summarizing data published since the 2017 American Heart Association Scientific Statement on Kawasaki Disease related to diagnostic criteria, risk scores and treatment options for children and adults with this condition.

Read Article
RheumNow Podcast square

Happy Diwali (11.1.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.

Read Article
juvDM1.jpg

Long-term Tofacitinib in Juvenile Idiopathic Arthritis

Jack Cush, MD

The long-term safety and efficacy of tofacitinib in patients with juvenile idiopathic arthritis (JIA) has been established in an ongoing long term extension (LTE) study.

Read Article
FDA has granted Rare Pediatric Disease Designation (RPDD) to a new proprietary investigational drug, 101-PCG-005, a type IA prodrug of dexamethasone targetsing CD206+ macrophages. The intended use is in systemic juvenile idiopathic arthritis (sJIA) or Still's disease .… https://t.co/ErNWlva9Nd https://t.co/gc8cPNs3H1
Dr. John Cush RheumNow ( View Tweet)
J&J has submitted 2 supplemental BLAs applying for FDA approval of guselkumab( Tremfya) for use in juvenile plaque psoriasis & juvenile (>5-6 yrs age) psoriatic arthritis based on several phase 3 RCTs. https://t.co/dAkH219pzN https://t.co/R9yJCSOVJa

Links:

Dr. John Cush RheumNow ( View Tweet)
EULAR and the Paediatric Rheumatology European Society (PReS) and FDA now view systemic juvenile idiopathic arthritis and adult-onset Still’s disease as a single entity — Still’s disease; based on overlapping tests, clinical manifestations, complications & response to biologics… https://t.co/OHfcFymdPx https://t.co/Wm2ciKbMtY
Dr. John Cush RheumNow ( View Tweet)
Standardizing Still’s Disease Research: Global Data Harmonization Needed A recent study presented at #ACR24 convergence highlights significant gaps and inconsistencies in the research of systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease (AOSD).… https://t.co/ugsfRj2fnS https://t.co/UJmNvAMo1c
Dr. John Cush RheumNow ( View Tweet)
A#2529 Disparities in JIA Outcome documentation, best practices, access to at-risk pts, agency and access - outcomes initially appeared to worsen - reflection of better documentation Improvement driven by pt global scores Disparity gap closed by 17% #ACR24 @RheumNow https://t.co/oOxs0jIvBK

Links:

Eric Dein ericdeinmd ( View Tweet)
Is it safe to administer rotavirus vaccine to infants exposed in utero to TNFi? Abstract#0806 shows no significant ↑ in the risk of diarrhea-related healthcare events among TNFi-exposed infants who received the vaccine compared to those who did not @RheumNow #ACR24 https://t.co/HpTCgywE4H

Links:

Akhil Sood MD AkhilSoodMD ( View Tweet)
CV risk factors in rheumatic dz patients start in childhood. Patients with PMH of Kawasaki disease are at risk for rca/lmca aneurysms, thrombosis and stroke. Important to consider this with our history taking when pediatric patients transition to adult care! @RheumNow #ACR24 https://t.co/CIp8PjW4vD

Links:

Gabriela Martinez Zayas, MD MartinezZayasMd ( View Tweet)
Diagnosis and Management of Kawasaki Disease The journal Circulation has published a comprehensive overview called “Update on Diagnosis and Management of Kawasaki Disease,” summarizing data published since the 2017 American Heart Association Scientific Statement on Kawasaki… https://t.co/rS5bDneplO https://t.co/nZ0GeIQD0T
Dr. John Cush RheumNow ( View Tweet)
Recomendations for the management of Kawasaki’s disease. Cardiometabolic session, Bryce Binstadt @RheumNow #ACR24 https://t.co/KftwMDYzH1

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Overview of Uveitis management of adult & pediatric rheumatology. - Uveitis accounts for 10% of visual impairment globally - TNF inhib are effective; w/ IL-6 inhib as 2nd line options https://t.co/CmGuA7W4Ag https://t.co/p5aEQlV7p6

Links:

Dr. John Cush RheumNow ( View Tweet)
Trends in DMARD Use in Juvenile Arthritis 2001-2022 Arthritis & Rheumatology reports that treatment trends in juvenile idiopathic arthritis (JIA) in the last two decades finds rising use of newer biologic and targeted synthetic DMARDs coupled with a decline in conventional… https://t.co/fEOvjm21lY https://t.co/LfDleabEQS
Dr. John Cush RheumNow ( View Tweet)
Long-term Tofacitinib in Juvenile Idiopathic Arthritis The long-term safety and efficacy of tofacitinib in patients with juvenile idiopathic arthritis (JIA) has been established in an ongoing long term extension (LTE) study. https://t.co/IKHM6z8iMB https://t.co/O6ig1lTQR4

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×